XML 90 R75.htm IDEA: XBRL DOCUMENT
v3.19.2

COMMITMENTS AND CONTINGENCIES - Narrative (Details) $ in Millions |  |  | 1 Months Ended | 3 Months Ended |  |  |  |  |
--- | --- | --- | --- | --- | --- | --- | --- | --- | ---
May 25, 2017 USD ($) | Feb. 24, 2017 USD ($) | Oct. 31, 2018 USD ($) | Aug. 31, 2017 USD ($) | Jun. 30, 2018 USD ($) | Jun. 30, 2019 USD ($) | Dec. 31, 2018 USD ($) | Mar. 31, 2018 USD ($) | Feb. 14, 2017 USD ($) | Jan. 15, 2014 USD ($)
Confluent Surgical, Inc. |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |
Maximum contingent consideration |  |  |  |  |  |  |  |  |  | $ 30.0
Contingent consideration, liability |  |  |  |  |  |  |  | $ 19.0 |  |
Payment for contingent consideration |  |  | $ 5.0 |  |  |  |  |  |  |
Confluent Surgical, Inc. | Measurement Input, Discount Rate | Contingent Consideration Liability |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |
Discounted cash flow model, measurement input |  |  |  |  |  |  |  |  |  | 0.022
Confluent Surgical, Inc. | Cash Consideration One |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |
Maximum contingent consideration |  |  |  |  |  |  |  |  |  | $ 25.0
Confluent Surgical, Inc. | Cash Consideration Two |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |
Maximum contingent consideration |  |  |  |  |  |  |  |  |  | $ 5.0
Derma Sciences | BioD Earnout Payments |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |
Maximum contingent consideration |  | $ 26.5 |  |  |  |  |  |  | $ 26.5 |
Contingent consideration, liability |  | $ 9.1 |  |  |  |  |  |  |  |
Payment for contingent consideration |  |  |  | $ 4.8 |  |  |  |  |  |
Revenue volatility percentage |  | 13.50% |  |  |  |  |  |  |  |
Derma Sciences | BioD Earnout Payments | Measurement Input, Discount Rate |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |
Discounted cash flow model, measurement input |  | 0.030 |  |  |  |  |  |  |  |
Derma Sciences | Product Payment Contingent Consideration |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |
Payment for contingent consideration liability | $ 26.6 |  |  |  |  |  |  |  |  |
Derma Sciences | Medihoney Earnout Payments |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |
Maximum contingent consideration |  | $ 5.0 |  |  |  |  |  |  |  |
Contingent consideration, liability |  |  |  |  | $ 0.2 | $ 0.2 | $ 0.2 |  |  |
Payment for contingent consideration |  |  |  |  | $ 2.0 |  |  |  |  |
Revenue volatility percentage |  | 27.50% |  |  |  |  |  |  |  |
Derma Sciences | Medihoney Earnout Payments | Measurement Input, Discount Rate |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |
Discounted cash flow model, measurement input |  | 0.045 |  |  |  |  |  |  |  |

X
- Definition Fair Value Inputs, Revenue Volatility + References No definition available. + Details
Name: | iart_FairValueInputsRevenueVolatility
Namespace Prefix: | iart_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition For contingent consideration arrangements recognized in connection with a business combination, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 50 -Paragraph 1 -Subparagraph (c)(3) -URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479 + Details
Name: | us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of liability recognized arising from contingent consideration in a business combination. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 50 -Paragraph 1 -Subparagraph (c)(1) -URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 35 -Paragraph 1 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 25 -Paragraph 6 -URI http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476 + Details
Name: | us-gaap_BusinessCombinationContingentConsiderationLiability
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Value of input used to measure debt instrument, including, but not limited to, convertible and non-convertible debt. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258 + Details
Name: | us-gaap_DebtInstrumentMeasurementInput
Namespace Prefix: | us-gaap_
Data Type: | xbrli:decimalItemType
Balance Type: | na
Period Type: | instant

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_LossContingenciesLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 15 -Subparagraph (f) -URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585 + Details
Name: | us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of cash outflow, made soon after acquisition date of business combination, to settle contingent consideration liability. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 13 -Subparagraph (d) -URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585 + Details
Name: | us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=iart_ConfluentSurgicalInc.Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FairValueByLiabilityClassAxis=iart_ContingentConsiderationLiabilityMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ContingentConsiderationByTypeAxis=iart_CashConsiderationOneMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ContingentConsiderationByTypeAxis=iart_CashConsiderationTwoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=iart_DermaSciencesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ContingentConsiderationByTypeAxis=iart_BioDEarnoutPaymentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ContingentConsiderationByTypeAxis=iart_ProductPaymentContingentConsiderationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ContingentConsiderationByTypeAxis=iart_MedihoneyEarnoutPaymentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |